(via NewsDirect)
Proactive research analyst
The ongoing NV-CoV-2 Phase Ia clinical study is a key milestone in the development of
The polymer is integrated into the product which has now entered a clinical trial in
The absence of safety concerns is noteworthy. The trial examines two administration routes: a gummy and a syrup. Crucially, the trial aims to determine blood levels and safety, laying the foundation for potential efficacy.
A subsequent trial will involve 36 mild-to-moderate COVID-19 patients. Despite the emergence of new virus strains,
Contact Details
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source